Vitamin K2 immunosuppressive effect on pediatric patients with atopic dermatitis
Vitamin K2 immunosuppressive effect on pediatric patients with atopic dermatitis
复制标题
DOI：
10.1111/ped.14014
复制
发表时间：
2019-12-13
影响因子：
1.4
通讯作者：
Hirano, Toshihiko
中科院分区：
文献类型：
--
作者：
Xu, Wencheng;Meng, Kehan;Hirano, Toshihiko
Background Over 20 kinds of steroids, tacrolimus ointments, and cyclosporine capsules are usually recommended for the treatment of atopic dermatitis (AD), depending on the symptoms of patients. However, several side effects sometimes occur with the extensive use of these agents for the treatment of pediatric AD patients. The purpose of this study was to explore whether vitamin K-2 could be a new immunosuppressive candidate for pediatric patients with AD. Methods The immunosuppressive efficacy of vitamin K-2 was evaluated through a cell-culture procedure using mitogen-activated peripheral blood mononuclear cells (PBMCs) obtained from pediatric AD patients. Results The mean (SD) IC50 value of vitamin K-2 for the proliferation of concanavalin A-activated PBMCs was 15.37 (30.05) mu mol/L, while the value for tacrolimus was 0.10 (0.28) ng/mL (0.12 (0.35) nmol/L). There was a significant correlation between the IC50 values for vitamin K-2 and those for tacrolimus (P = 0.0001, r = 0.8871). However, there was no significant correlation between the IC50 values of vitamin K-2 and those of cyclosporine A or methylprednisolone. A significant correlation between the IC50 values of vitamin K-2 or tacrolimus and blood eosinophil counts (P = 0.0099, r = 0.7086 and P = 0.0032, r = 0.7722, respectively) was observed. Conclusion Vitamin K-2-inhibited T-cell mitogen stimulated proliferation of PBMCs from pediatric AD patients in a dose-dependent manner. The PBMCs from pediatric AD patients were more sensitive to the immunosuppressive efficacy of vitamin K-2 than the PBMCs from healthy subjects. The individual immunosuppressive pharmacological efficacy of vitamin K-2 and of tacrolimus could be inferred from the blood eosinophil count of pediatric AD patients.
